Skip to content

Second serosurveillance study in the Netherlands for the evaluation of the Dutch National Immunisation Programme: the PIENTER 2 study.

Second serosurveillance study in the Netherlands for the evaluation of the Dutch National Immunisation Programme: the PIENTER 2 study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23975
Enrollment
7700
Registered
2007-05-16
Start date
2006-02-06
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Diseases, Vaccines, National Immunisation Program

Interventions

A blood sample and a questionnaire regarding health perception, diseases (including sexually transmitted), vaccination data.

Sponsors

National Institute for Public Health and the Environment (RIVM)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subject is part of the study sample; 2. Aged 0-79 years old; 3. Has received a personal invitation for the study; 4. Subject has given written informed consent before start of the study.

Exclusion criteria

Exclusion criteria: 1 Subject is an employee of the RIVM.

Design outcomes

Primary

MeasureTime frame
The age-specific seroprevalence (immunity) for diseases included in the National Immunisation Program of the Dutch general population.

Secondary

MeasureTime frame
1. The age-specific seroprevalence against other infectious diseases, in particular those that might be vaccin preventable in the near future and against those diseases with a frequent subclinical course. 2. The age-specific seroprevalence amongst the allochtonous populations (additional sample). 3. The age-specific seroprevalence amongst non-vaccinated orthodox reformed individuals (additional sample).

Contacts

Public ContactF.R.M Klis, van der

RIVM, afd. LIS P.O. Box 1

fiona.van.der.klis@rivm.nl(+31) 30 2742272

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)